Targeting hypoxic prostate tumours using the novel hypoxia-activated prodrug OCT1002 inhibits expression of genes associated with malignant progression

Heather Nesbitt, Niall Byrne, Louise Ming, Jenny Worthington, Rachel Errington, Laurence Patterson, Paul Smith, Stephanie McKeown, Declan McKenna

Research output: Contribution to journalArticlepeer-review

2 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Targeting hypoxic prostate tumours using the novel hypoxia-activated prodrug OCT1002 inhibits expression of genes associated with malignant progression'. Together they form a unique fingerprint.

Medicine & Life Sciences